35838-58-5

Basic information

• Product Name: ETAZOLATE
• Synonyms: 1-ethyl-4-[(1-methylethylidene)hydrazino]1h-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester hydrochloride;SQ20009, 1-Ethyl-4-[(1-methylethylidene)hydrazino]1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester hydrochloride;1H-Pyrazolo[3,4-B]pyridine-5-carboxylic acid, 1-ethyl-4-[(1-methylethylidene)hydrazino]-, ethyl ester, monohydrochloride;Ethyl 1-ethyl-4-(isopropylidenehydrazino)-1H-pyrazolo[3,4-B]pyridine-5-carboxylate monohydrochloride;Nsc163611
• CAS NO: 35838-58-5
• Molecular Formula: C14H18N5O2HCl
• Molecular Weight: 0
• Mol File: 35838-58-5.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 427.6°Cat760mmHg
• Flash Point: 212.4°C
• Appearance: white/
• Density: 1.25g/cm³
• Vapor Pressure: 1.61E-07mmHg at 25°C
• Storage Temp.: room temp
• Solubility: H2O: >20mg/mL (Solutions should be freshly prepared.)
• CAS DataBase Reference: ETAZOLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETAZOLATE(35838-58-5)
• EPA Substance Registry System: ETAZOLATE(35838-58-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 35838-58-5(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 35838-58-5 differently. You can refer to the following data:
1. Antipsychotic.
2. Etazolate Hydrochloride is an acyclic nucleotide phosphodiesterase 4 inhibitor, which also exhibits antidepressant-like activity in acute and chronic mouse and rat model of depression.

Biological Activity

etazolate hydrochloride is a pde-4 inhibitor and selective gaba-a receptor modulator [3].pde-4 modulates the release of inflammatory mediators through camp-dependent and -independent mechanisms. selective targeting pde-4 is a novel therapeutic approach in the treatment of inflammation-associated respiratory diseases, such as asthma and copd (chronic obstructive pulmonary disease) [1].in rat neuronal cortical cells, etazolate hydrochloride (0.2 μm) induced sappα through the stimulation of the α-secretase pathway, and exerted a neuroprotective effect against aβ which was associated with sappα induction via the gaba-a receptor [2].in 159 alzheimer’s disease patients, etazolate hydrochloride in combination with one achei (acetycholinesterase inhibitor) was shown to be safe and generally well tolerated in the phase iia study over a 3-month treatment period [3].

Biochem/physiol Actions

Selective inhibitor of cAMP-specific phosphodiesterase.

references

[1] dastidar s g, rajagopal d, ray a. therapeutic benefit of pde4 inhibitors in inflammatory diseases.[j]. current opinion in investigational drugs, 2007, 8(5):364-72. [2] marcade m, bourdin j, loiseau n, et al. etazolate, a neuroprotective drug linking gaba(a) receptor pharmacology to amyloid precursor protein processing.[j]. journal of neurochemistry, 2008, 106(1):392-404.[3] vellas b; sol o; snyder pj; ousset pj; haddad r; maurin m; lemarié jc; désiré l; pando mp; eht0202/002 study group. eht0202 in alzheimer's disease: a 3-month, randomized, placebo-controlled, double-blind study.[j]. current alzheimer research, 2011, 8(2):203-12.

InChI:InChI=1/C14H19N5O2.ClH/c1-5-19-13-10(8-16-19)12(18-17-9(3)4)11(7-15-13)14(20)21-6-2;/h7-8H,5-6H2,1-4H3,(H,15,18);1H